MedTrace Logo

Single Center Registration Study on HER2 Expression and Clinical Pathological Characteristics in Prostate Cancer

NCT06146114 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2023-11-24

No results posted yet for this study

Summary

This study is a single center, non-interference, retrospective registration study: HER2 testing and disease information collection were conducted on patients diagnosed with prostate cancer and able to obtain tumor tissue in our hospital from January 2018 to July 2023. Statistical analysis was conducted on the collected information to analyze the expression of HER2 in Chinese prostate patients and the correlation between HER2 and disease type.

Conditions

  • HER2 Expression and Clinical Pathological Characteristics in Prostate Cancer

Interventions

DIAGNOSTIC_TEST

Collect HER2 expression in prostate cancer patients

HER2 testing and disease information collection for patients diagnosed with prostate cancer and able to obtain tumor tissue in our hospital from January 2018 to July 2023

Sponsors & Collaborators

  • Qilu Hospital of Shandong University

    lead OTHER

Eligibility

Min Age
50 Years
Max Age
90 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-01
Primary Completion
2024-05-01
Completion
2024-12-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06146114 on ClinicalTrials.gov